Ontology highlight
ABSTRACT: Methods
To determine whether every 2-mo (q2m) belatacept is noninferior to standard q1m maintenance, we conducted a prospective, single-center randomized trial in low-immunologic-risk, stable renal transplant recipients. Here, post hoc analysis of 3-y outcomes, including renal function and adverse events, are reported.Results
One hundred sixty-three patients received treatment in the q1m control group (n = 82) or q2m study group (n = 81). Renal allograft function as m
SUBMITTER: Johnson AC
PROVIDER: S-EPMC9977481 | biostudies-literature | 2023 Mar
REPOSITORIES: biostudies-literature